Saba Capital Management’s Ibere Pharmaceuticals IBER Stock Holding History

Saba Capital Management’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-355,704	Closed	-$3.59M	–	942
2022 Q4	$3.59M	Buy	355,704 +26,700	+8%	+$267K	0.05%	448
2022 Q3	$3.26M	Buy	329,004 +249,027	+311%	+$2.46M	0.04%	584
2022 Q2	$785K	Hold	79,977	–	–	0.01%	723
2022 Q1	$785K	Buy	+79,977	New	+$779K	0.01%	651

Saba Capital Management's IBER Position: Q1 2023 in Review

Saba Capital Management sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 355,704 shares — an estimated $3.59M sold.

Saba Capital Management first reported a position in IBER in Q1 2022 and held it in 4 quarters. The position peaked at $3.59M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Saba Capital Management reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Saba Capital Management sold 355,704 Ibere Pharmaceuticals shares in Q1 2023, an estimated $3.59M.
Saba Capital Management first reported a position in Ibere Pharmaceuticals in Q1 2022 and held it in 4 quarters.
Saba Capital Management's Ibere Pharmaceuticals position peaked at $3.59M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Saba Capital Management's 13F filing for Q1 2023, filed 15 May 2023.